Clinical Cancer Research · 2007 · 40 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyComplement SystemHybridoma TechnologyMonoclonal Antibody TechnologyMonoclonal Antibody TherapyTherapeutic Antibody DevelopmentAntitumor Immune ActivationComplement In CancerIgm-mediated CytotoxicityJoining Gene SegmentsMelanoma ImmunotherapyMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyMonoclonal Antibody Therapeutics
PURPOSE: L612, a human IgM monoclonal antibody produced by an EBV-transformed human B-cell line, binds to ganglioside GM3 and kills GM3-positive human melanoma cells in the presence of complement. It has been shown to be effective in some patients with late-stage melanoma. L612 consists of hexameric IgM (about 20%), pentameric IgM (about 74%), and other minor IgM molecules. Because hexameric IgM activates complement more effectively than pentameric IgM, we developed and evaluated a hexamer-dominant recombinant IgM for clinical applications. EXPERIMENTAL DESIGN: Chinese hamster ovary (CHO) cells were transfected with heavy- and light-chain genes of L612, with or without the joining-chain gene. Antitumor effects of the recombinant IgM secreted from CHO cells were evaluated in vitro and in vivo. RESULTS: Recombinant IgM secreted from CHO cells without the joining chain (designated CA19) was approximately 80% hexameric, whereas recombinant IgM from CHO cells transfected with heavy-, light-, and joining-chain genes (designated CJ45) was about 90% pentameric. Both CA19 and CJ45 recombinant IgMs caused complement-dependent cytotoxicity against human and mouse melanoma cell lines, but the amount of CA19 required for 50% specific cytotoxicity was 5 to 10 times smaller. I.v. injection of CA19 compared with CJ45 or native L612 elicited more profound antitumor activity in nude rats bearing a GM3-positive mouse melanoma xenograft. CONCLUSIONS: A hexamer-dominant human IgM against GM3 may provide a more potent treatment option for patients with GM3-positive melanoma.
25
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Immunogenicity of melanoma‐associated gangliosides in cancer patients
Tadashi Tai, Leslie D. Cahan, Tetsuya Tsuchida et al. · International Journal of Cancer · 1985 · 166 citations
Medicine, Immunology, Oncology +17
Ulrich Keilholz, Cornelis J.A. Punt, Martin Gore et al. · Journal of Clinical Oncology · 2005 · 166 citations · Full text
Medicine, Oncology, Pharmacology +17